Upgrade to SI Premium - Free Trial

AnaptysBio (ANAB) PT Lowered to $60 at UBS Following Spinoff of Biopharma Business

April 21, 2026 9:25 AM
UBS analyst Michael Yee lowered the price target on AnaptysBio (NASDAQ: ANAB) to $60.00 (from $90.00) while maintaining a Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change